{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:41Z","timestamp":1793747081098,"version":"4.6.1"},"reference-count":199,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cholangiocarcinoma (CCA) is the second most common primary liver cancer and subsumes a heterogeneous group of malignant tumors arising from the intra- or extrahepatic biliary tract epithelium. A rising mortality from CCA has been reported worldwide during the last decade, despite significant improvement of surgical and palliative treatment. Over 50% of CCAs originate from proximal extrahepatic bile ducts and constitute the most common CCA entity in the Western world. Clinicopathological characteristics such as lymph node status and poor differentiation remain the best-studied, but imperfect prognostic factors. The identification of prognostic molecular markers as an adjunct to traditional staging systems may not only facilitate the selection of patients who would benefit the most from surgical, adjuvant or palliative treatment strategies, but may also be helpful in defining the aggressiveness of the disease and identifying patients at high-risk for tumor recurrence. The purpose of this review is to provide an overview of currently known molecular prognostic and predictive markers and their role in CCA.<\/jats:p>","DOI":"10.3390\/cancers14041026","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:24:26Z","timestamp":1645129466000},"page":"1026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Prognostic and Predictive Molecular Markers in Cholangiocarcinoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-2466","authenticated-orcid":false,"given":"Sandra","family":"Pavicevic","sequence":"first","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-046X","authenticated-orcid":false,"given":"Sophie","family":"Reichelt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-0845","authenticated-orcid":false,"given":"Deniz","family":"Uluk","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-7707","authenticated-orcid":false,"given":"Isabella","family":"Lurje","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik P.","family":"Modest","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-2737","authenticated-orcid":false,"given":"Uwe","family":"Pelzer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9917","authenticated-orcid":false,"given":"Felix","family":"Krenzien","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-7063","authenticated-orcid":false,"given":"Nathanael","family":"Raschzok","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Benzing","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-937X","authenticated-orcid":false,"given":"Igor M.","family":"Sauer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cancer Immunology, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel","family":"Sch\u00f6ning","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Schmelzle","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Pratschke","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-0756","authenticated-orcid":false,"given":"Georg","family":"Lurje","sequence":"additional","affiliation":[{"name":"Department of Surgery, Campus Charit\u00e9 Mitte, Campus Virchow Klinikum, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clcc.2019.02.005","article-title":"Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma","volume":"18","author":"Saeed","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"\u00d6zdirik, B., M\u00fcller, T., Wree, A., Tacke, F., and Sigal, M. (2021). The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136975"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ejso.2019.04.019","article-title":"The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma","volume":"45","author":"Lurje","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.hpb.2019.07.003","article-title":"Left- versus right-sided hepatectomy with hilar en-bloc resection in perihilar cholangiocarcinoma","volume":"22","author":"Bednarsch","year":"2020","journal-title":"HPB"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1245\/s10434-019-08192-z","article-title":"ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-Center Study","volume":"27","author":"Li","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1089\/lap.2020.0215","article-title":"Laparoscopic Liver Resection for Intrahepatic Cholangiocarcinoma: A Single-Center Experience","volume":"30","author":"Haber","year":"2020","journal-title":"J. Laparoendosc. Adv. Surg. Tech."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10353-017-0507-8","article-title":"Hilar en bloc resection for hilar cholangiocarcinoma in patients with limited liver capacities\u2014Preserving parts of liver segment 4","volume":"50","author":"Jonas","year":"2018","journal-title":"Eur. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Krenzien, F., Nevermann, N., Krombholz, A., Benzing, C., Haber, P., Fehrenbach, U., Lurje, G., Pelzer, U., Pratschke, J., and Schmelzle, M. (2022). Treatment of Intrahepatic Cholangiocarcinoma\u2014A Multidisciplinary Approach. Cancers, 14.","DOI":"10.3390\/cancers14020362"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00104-018-0718-y","article-title":"Aktueller Therapiealgorithmus des intrahepatischen cholangiozellul\u00e4ren Karzinoms","volume":"89","author":"Lurje","year":"2018","journal-title":"Der Chir."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.ejso.2019.05.030","article-title":"Reply to: Does lymphovascular invasion really associate with decreased overall survival for patients with resected cholangiocarcinoma?","volume":"45","author":"Bednarsch","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00104-019-01062-0","article-title":"Chirurgische Therapie maligner Gallengangserkrankungen","volume":"91","author":"Schmelzle","year":"2019","journal-title":"Der Chirurg"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hpb.2020.04.017","article-title":"Insufficient future liver remnant and preoperative cholangitis predict perioperative outcome in perihilar cholangiocarcinoma","volume":"23","author":"Bednarsch","year":"2020","journal-title":"HPB"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00423-019-01838-2","article-title":"The role of ALPPS in intrahepatic cholangiocarcinoma","volume":"404","author":"Bednarsch","year":"2019","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/SLA.0000000000005110","article-title":"Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation from Donation After Brain Death","volume":"274","author":"Czigany","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/aor.14103","article-title":"Hypothermic oxygenated machine perfusion for extended criteria donor allografts\u2014Preliminary experience with extended organ preservation times in the setting of organ reallocation","volume":"46","author":"Pavicevic","year":"2021","journal-title":"Artif. Organs"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lauterio, A., De Carlis, R., Centonze, L., Buscemi, V., Incarbone, N., Vella, I., and De Carlis, L. (2021). Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma. Cancers, 13.","DOI":"10.3390\/cancers13153657"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/SLA.0000000000002834","article-title":"Transplantation Versus Resection for Hilar Cholangiocarcinoma","volume":"269","author":"Vibert","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: Predictive or Prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","unstructured":"FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and Other Tools) Resource [Internet]."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Czigany, Z., Lurje, I., Schmelzle, M., Sch\u00f6ning, W., \u00d6llinger, R., Raschzok, N., Sauer, I.M., Tacke, F., Strnad, P., and Trautwein, C. (2020). Ischemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical Implications. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030846"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","article-title":"Tumor Marker Utility Grading System: A Framework to Evaluate Clinical Utility of Tumor Markers","volume":"88","author":"Hayes","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.31175","article-title":"Biomarkers for Hepatobiliary Cancers","volume":"73","author":"Nault","year":"2020","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Churi, C.R., Shroff, R., Wang, Y., Rashid, A., Kang, H., Weatherly, J., Zuo, M., Zinner, R., Hong, D., and Meric-Bernstam, F. (2014). Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115383"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.hpb.2019.03.363","article-title":"Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma","volume":"21","author":"Bolm","year":"2019","journal-title":"HPB"},{"key":"ref_32","first-page":"7890","article-title":"Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma","volume":"7","author":"Cai","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/jgh.13059","article-title":"Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma","volume":"31","author":"Lee","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12659\/MSM.895040","article-title":"Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"21","author":"Liang","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16975","DOI":"10.1038\/s41598-017-17175-7","article-title":"CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma","volume":"7","author":"Loosen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e6016931","DOI":"10.1155\/2019\/6016931","article-title":"Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma","volume":"2019","author":"Fang","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.7314\/APJCP.2015.16.8.3451","article-title":"Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma","volume":"16","author":"Li","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cca.2018.02.008","article-title":"The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma","volume":"480","author":"Qiu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11605-013-2447-3","article-title":"Survival Outcomes and Prognostic Factors of Surgical Therapy for All Potentially Resectable Intrahepatic Cholangiocarcinoma: A Large Single-Center Cohort Study","volume":"18","author":"Luo","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100242","DOI":"10.1016\/j.aohep.2020.07.010","article-title":"Carcinoembryonic antigen, \u03b1-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study","volume":"20","author":"Qiang","year":"2020","journal-title":"Ann. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1245\/s10434-020-08350-8","article-title":"The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma","volume":"27","author":"Moro","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.7150\/jca.25339","article-title":"Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma","volume":"9","author":"He","year":"2018","journal-title":"J. Cancer"},{"key":"ref_43","first-page":"1273","article-title":"Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"60","author":"Huang","year":"2014","journal-title":"Am. J. Dig. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1478-3231.2007.01577.x","article-title":"Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis","volume":"27","author":"Itatsu","year":"2007","journal-title":"Liver Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jhep.2017.06.020","article-title":"Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma","volume":"67","author":"Loosen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"582","DOI":"10.21037\/hbsn.2019.03.14","article-title":"Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma","volume":"8","author":"Zhou","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1245\/s10434-015-4782-y","article-title":"Prognostic Impact of Peritumoral IL-17-Positive Cells and IL-17 Axis in Patients with Intrahepatic Cholangiocarcinoma","volume":"22","author":"Asukai","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.jhepr.2020.100080","article-title":"Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer","volume":"2","author":"Loosen","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3748\/wjg.v18.i3.244","article-title":"High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis","volume":"18","author":"Thummarati","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clinbiochem.2014.01.030","article-title":"Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients","volume":"47","author":"Grunnet","year":"2014","journal-title":"Clin. Biochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/17474124.2021.1912591","article-title":"Prognostic biomarkers for cholangiocarcinoma (CCA): State of the art","volume":"15","author":"Lang","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.18632\/oncotarget.14530","article-title":"Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection","volume":"8","author":"Jing","year":"2016","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2147\/CMAR.S158155","article-title":"Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: A systematic review and meta-analysis","volume":"10","author":"Sun","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clinre.2016.10.007","article-title":"Identification of microRNAs as biomarkers for cholangiocarcinoma detection: A diagnostic meta-analysis","volume":"41","author":"Zhou","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.dld.2016.07.006","article-title":"Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma","volume":"48","author":"Liang","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Loosen, S.H., Lurje, G., Wiltberger, G., Vucur, M., Koch, A., Kather, J.N., Paffenholz, P., Tacke, F., Ulmer, F.T., and Trautwein, C. (2019). Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210944"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/liv.14090","article-title":"Diagnostic and prognostic biomarkers in cholangiocarcinoma","volume":"39","author":"Macias","year":"2019","journal-title":"Liver Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e23397","DOI":"10.1002\/jcla.23397","article-title":"The association between circulating MicroRNA-150 level and cholangiocarcinoma","volume":"34","author":"Salem","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cca.2016.05.007","article-title":"Screening for circulating RAS\/RAF mutations by multiplex digital PCR","volume":"458","author":"Andersen","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1158\/1078-0432.CCR-07-5165","article-title":"Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab","volume":"14","author":"Lurje","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/annonc\/mdn368","article-title":"Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer","volume":"19","author":"Lurje","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/annonc\/mdp280","article-title":"Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma","volume":"21","author":"Lurje","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181c97fcf","article-title":"Genetic Variations in Angiogenesis Pathway Genes Predict Tumor Recurrence in Localized Adenocarcinoma of the Esophagus","volume":"251","author":"Lurje","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1053\/j.gastro.2020.04.058","article-title":"Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi\u2217Z Variant of AAT (Pi\u2217MZ vs. Pi\u2217ZZ genotype) and Noncarriers","volume":"159","author":"Schneider","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lurje, I., Czigany, Z., Bednarsch, J., Gaisa, N.T., Dahl, E., Kn\u00fcchel, R., Miller, H., Ulmer, T.F., Strnad, P., and Trautwein, C. Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma. Liver Cancer, 2022. in press.","DOI":"10.1159\/000521613"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/07357900903095714","article-title":"Prognostic Assessment of Three Single-Nucleotide Polymorphisms (GNB3825C>T,BCL2-938C>A,MCL1-386C>G) in Extrahepatic Cholangiocarcinoma","volume":"28","author":"Fingas","year":"2009","journal-title":"Cancer Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/liv.14085","article-title":"Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?","volume":"39","author":"Braconi","year":"2019","journal-title":"Liver Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187231207779814328","article-title":"ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan","volume":"1","author":"Rhodes","year":"2007","journal-title":"Drug Metab. Lett."},{"key":"ref_69","first-page":"e392652","article-title":"Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications","volume":"2010","author":"Lurje","year":"2009","journal-title":"J. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e10464","DOI":"10.7717\/peerj.10464","article-title":"ARID1A alterations and their clinical significance in cholangiocarcinoma","volume":"8","author":"Namjan","year":"2020","journal-title":"PeerJ"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/ajcp\/aqw071","article-title":"Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas","volume":"145","author":"Sasaki","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bi, C., Liu, M., Rong, W., Wu, F., Zhang, Y., Lin, S., Liu, Y., Wu, J., and Wang, L. (2019). High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: A histopathological retrospective study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5429-3"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1245\/s10434-013-3286-x","article-title":"Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis","volume":"21","author":"Ruys","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/BMM.15.48","article-title":"Prognostic molecular markers in resected extrahepatic biliary tract cancers: A systematic review and meta-analysis of immunohistochemically detected biomarkers","volume":"9","author":"Jones","year":"2015","journal-title":"Biomarkers Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2017.09.005","article-title":"Characterisation of the immune-related transcriptome in resected biliary tract cancers","volume":"86","author":"Ghidini","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.2147\/OTT.S141476","article-title":"CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma","volume":"ume 10","author":"Huang","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/cas.12967","article-title":"CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment","volume":"107","author":"Thanee","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14737140.2018.1467760","article-title":"Prognostic biomarkers for cholangiocarcinoma and their clinical implications","volume":"18","author":"Saengboonmee","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wan, M., Zhou, Q., Wang, H., Wang, Z., Zhong, X., Zhang, L., Tai, S., and Cui, Y. (2015). The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141165"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2015.12.027","article-title":"Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma","volume":"52","author":"Talabnin","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.1007\/s13277-015-4704-4","article-title":"Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3892\/or.2016.4807","article-title":"Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma","volume":"36","author":"Zhao","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13277-014-2651-0","article-title":"Hepatoma-derived growth factor: A novel prognostic biomarker in intrahepatic cholangiocarcinoma","volume":"36","author":"Guo","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/CBM-140393","article-title":"Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma","volume":"14","author":"Zhao","year":"2014","journal-title":"Cancer Biomark."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbrc.2014.08.124","article-title":"SOX4 is associated with poor prognosis in cholangiocarcinoma","volume":"452","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1078-0432.CCR-18-0124","article-title":"Serum Nardilysin, a Surrogate Marker for Epithelial\u2013Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection","volume":"25","author":"Yoh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.3748\/wjg.v11.i32.4939","article-title":"MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma","volume":"11","author":"Boonla","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ejso.2015.07.006","article-title":"Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy","volume":"41","author":"Abe","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jss.2014.05.017","article-title":"Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma","volume":"192","author":"Sulpice","year":"2014","journal-title":"J. Surg. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jss.2016.03.044","article-title":"Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma","volume":"203","author":"Bergeat","year":"2016","journal-title":"J. Surg. Res."},{"key":"ref_92","first-page":"6157","article-title":"High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma","volume":"7","author":"Sun","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.7314\/APJCP.2015.16.9.3697","article-title":"High Expression of Matrix Metalloproteinase-11 indicates Poor Prognosis in Human Cholangiocarcinoma","volume":"16","author":"Tongtawee","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_94","first-page":"8376","article-title":"Interleukin-8 is a prognostic indicator in human hilar cholangiocarcinoma","volume":"8","author":"Sun","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopha.2017.05.061","article-title":"Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition","volume":"92","author":"Xu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.2147\/OTT.S137044","article-title":"Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma","volume":"10","author":"Xu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhang, M.-Y., Li, S.-H., Huang, G.-L., Lin, G.-H., Shuang, Z.-Y., Lao, X.-M., Xu, L., Lin, X.-J., Wang, H.-Y., and Li, S.-P. (2015). Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1067-6"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000455869","article-title":"Increased Expression of miR-29a and Its Prognostic Significance in Patients with Cholangiocarcinoma","volume":"40","author":"Deng","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-018-1475-x","article-title":"Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis","volume":"16","author":"Ikeno","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L.H., Kl\u00fcmpen, H.-J., Lohse, A.W., Nashan, B., Primrose, J., and Schrum, S. (2015). Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)\u2014A randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1498-0"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion\u2013Positive Cholangiocarcinoma","volume":"7","author":"Goyal","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.08.027","article-title":"Targeting cholangiocarcinoma","volume":"1864","author":"Mertens","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10637-016-0416-x","article-title":"Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: A Phase I study","volume":"35","author":"Saka","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1158\/1078-0432.CCR-18-1881","article-title":"A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers","volume":"25","author":"Kurzrock","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2020.38.15_suppl.108","article-title":"FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements","volume":"38","author":"Goyal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients with FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"viii720","DOI":"10.1093\/annonc\/mdy424.030","article-title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions","volume":"29","author":"Javle","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: The PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Futur. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"TPS600","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS600","article-title":"A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)","volume":"38","author":"Borad","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Valle","year":"2020","journal-title":"Futur. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0046-8177(98)90229-5","article-title":"Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis","volume":"29","author":"Terada","year":"1998","journal-title":"Hum. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdu157","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Simile, M.M., Bagella, P., Vidili, G., Spanu, A., Manetti, R., Seddaiu, M.A., Babudieri, S., Madeddu, G., Serra, P.A., and Altana, M. (2019). Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina, 55.","DOI":"10.3390\/medicina55020042"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.3748\/wjg.14.7033","article-title":"Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma","volume":"14","author":"Sirica","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","article-title":"EGFR Signaling and Drug Discovery","volume":"77","author":"Lurje","year":"2009","journal-title":"Oncology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients with Unresectable Biliary Cancer: A Phase II Consortium Study","volume":"28","author":"Lubner","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","article-title":"Phase II Study of Erlotinib in Patients with Advanced Biliary Cancer","volume":"24","author":"Philip","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","article-title":"HER2\/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mds008","article-title":"Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer","volume":"23","author":"Jensen","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2015","journal-title":"Cancer"},{"key":"ref_134","first-page":"382","article-title":"Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma","volume":"55","author":"Hoegdall","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target?","volume":"36","author":"Galdy","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000479970","article-title":"Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study","volume":"94","author":"Larsen","year":"2017","journal-title":"Oncology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: A phase 2 study","volume":"11","author":"Zhu","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/COC.0000000000000347","article-title":"A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer","volume":"41","author":"Iyer","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial","volume":"102","author":"Bengala","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_143","first-page":"1646","article-title":"SWOG 0514: A phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"Rankin","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2018","journal-title":"Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1002\/cncr.32964","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Macarulla","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-13-2649","article-title":"Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma","volume":"20","author":"Borger","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2020.01.026","article-title":"Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer","volume":"130","author":"Kim","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-Institutional Phase II Study of Selumetinib in Patients with Metastatic Biliary Cancers","volume":"29","author":"Phelps","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00432-006-0166-9","article-title":"Dual blockade of the Hedgehog and ERK1\/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells","volume":"133","author":"Jinawath","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1245\/s10434-007-9650-y","article-title":"Serum Cytokeratin 19 Fragment (CYFRA21-1) as a Prognostic Factor in Intrahepatic Cholangiocarcinoma","volume":"15","author":"Uenishi","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/0973-1482.193125","article-title":"Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma","volume":"14","author":"Liu","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/jhbp.145","article-title":"Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: A prospective prognostic indicator","volume":"21","author":"Silakit","year":"2014","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"16103","DOI":"10.1038\/srep16103","article-title":"Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma","volume":"5","author":"Cheng","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"18631","DOI":"10.18632\/oncotarget.4072","article-title":"Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3892\/ol.2013.1559","article-title":"A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma","volume":"6","author":"Paolicchi","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7314\/APJCP.2014.15.1.299","article-title":"Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients","volume":"15","author":"Khunluck","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1010428317694319","DOI":"10.1177\/1010428317694319","article-title":"Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma","volume":"39","author":"Meng","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1499-3872(14)60278-2","article-title":"CD98 is a promising prognostic biomarker in biliary tract cancer","volume":"13","author":"Kaira","year":"2014","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.29764","article-title":"Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma","volume":"68","author":"Nepal","year":"2018","journal-title":"Hepatology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/bjc.2011.199","article-title":"Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma","volume":"105","author":"Miyamoto","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"70378","DOI":"10.18632\/oncotarget.11859","article-title":"Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma","volume":"7","author":"Shi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.27788","article-title":"High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery","volume":"119","author":"Shi","year":"2012","journal-title":"Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00428-018-2478-y","article-title":"Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma","volume":"474","author":"Sarcognato","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Li, B., Tang, H., Zhang, A., and Dong, J. (2016). Prognostic Role of Mucin Antigen MUC4 for Cholangiocarcinoma: A Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157878"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000335164","article-title":"Pathobiological Implications of MUC16\/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type","volume":"79","author":"Higashi","year":"2012","journal-title":"Pathobiology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s13277-013-0688-0","article-title":"Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis","volume":"34","author":"Chusorn","year":"2013","journal-title":"Tumor Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1724600817751524","article-title":"The role of miR-92b in cholangiocarcinoma patients","volume":"33","author":"Zhou","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1359-x","article-title":"microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta\/Smad pathway","volume":"15","author":"Qiao","year":"2015","journal-title":"BMC Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/hep.28781","article-title":"N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor\/MicroRNA-181c negative feedback pathway","volume":"64","author":"Wang","year":"2016","journal-title":"Hepatology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hep.29116","article-title":"MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"ref_179","first-page":"1693","article-title":"miR-373 Negatively Regulates Methyl-CpG-Binding Domain Protein 2 (MBD2) in Hilar Cholangiocarcinoma","volume":"56","author":"Chen","year":"2010","journal-title":"Am. J. Dig. Dis."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Li, J., Yao, L., Li, G., Ma, D., Sun, C., Gao, S., Zhang, P., and Gao, F. (2015). miR-221 Promotes Epithelial-Mesenchymal Transition through Targeting PTEN and Forms a Positive Feedback Loop with \u03b2-catenin\/c-Jun Signaling Pathway in Extra-Hepatic Cholangiocarcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141168"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Bridgewater, J., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H., and Valle, J.W. (2016). A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: The ABC-04 study. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2174-8"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/cas.13438","article-title":"Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine","volume":"109","author":"Ikeda","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10637-016-0406-z","article-title":"A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers","volume":"35","author":"Goff","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2011-0253","article-title":"Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101","volume":"17","author":"Chiorean","year":"2012","journal-title":"Oncologist"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Kim, S.T., Jang, K.-T., Lee, S.J., Jang, H.-L., Lee, J., Park, S.H., Park, Y.S., Lim, H.Y., Kang, W.K., and Park, J.O. (2015). Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1552-y"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Moehler, M., Maderer, A., Ehrlich, A., Foerster, F., Schad, A., Nickolay, T., Ruckes, C., Weinmann, A., Sivanathan, V., and Marquardt, J.U. (2019). Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine\/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase I trial with an extensive biomarker program. BMC Cancer, 19.","DOI":"10.1186\/s12885-018-5223-7"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Jeong, H., Jeong, J., Kim, K.-P., Lee, S., Oh, D., Park, D., Song, T., Park, Y., Hong, S.-M., and Ryoo, B.-Y. (2021). Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. Cancers, 13.","DOI":"10.3390\/cancers13020161"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1407-e136","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.2147\/CMAR.S254955","article-title":"Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study","volume":"12","author":"Hu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_191","first-page":"3965","article-title":"Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e646979","DOI":"10.3389\/fonc.2021.646979","article-title":"The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients with Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"929","DOI":"10.21873\/anticanres.14026","article-title":"First Line Gemcitabine\/Pazopanib in Locally Advanced and\/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study","volume":"40","author":"Sgouros","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: The VanGogh study","volume":"26","author":"Santoro","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2018.36.4_suppl.427","article-title":"A multicenter phase ib-IIR trial assessing activity of regorafenib in combination with modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC)","volume":"36","author":"Assenat","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1002\/cncr.33803","article-title":"A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Ueno, M., Ikeda, M., Sasaki, T., Nagashima, F., Mizuno, N., Shimizu, S., Ikezawa, H., Hayata, N., Nakajima, R., and Morizane, C. (2020). Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07365-4"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1002\/cam4.4110","article-title":"Merestinib monotherapy or in combination for japanese patients with advanced and\/or metastatic cancer: A phase 1 study","volume":"10","author":"Doi","year":"2021","journal-title":"Cancer Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"17588359211036544","DOI":"10.1177\/17588359211036544","article-title":"IMbrave 151: A randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","volume":"13","author":"Hack","year":"2021","journal-title":"Ther. Adv. Med Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/1026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:21:53Z","timestamp":1760134913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/1026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":199,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14041026"],"URL":"https:\/\/doi.org\/10.3390\/cancers14041026","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}